Search

Displaying results 2311 - 2320 of 8575 in total
  1. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol was given FDA approval in 2019[FDA Label].

  2. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

  3. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    It has an approximate molecular weight of 148 kDa.

  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.

  6. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … [L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]

  7. Drug

    BMS-488043

    go.drugbank.com/drugs/DB05532
    Experimental

    BMS-488043 has been investigated as an anti-HIV agent.

  8. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.

  9. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib]. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

    Synonyms: 1,3,5-triazine-2,4-diamine, 6-(6-chloro-2-pyridinyl)-n2,n4-bis((1r)-2,2,2-trifluoro-1-methylethyl)-
  10. Drug

    Green tea leaf

    go.drugbank.com/drugs/DB14307
    Investigational

    Green tea leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Tea Bags